The estimated Net Worth of Dietrich A Lipizzaner Llc S... is at least $3.68 Million dollars as of 9 June 2020. Dietrich S owns over 1,275 units of NeuBase Therapeutics stock worth over $4,734 and over the last 5 years he sold NBSE stock worth over $0. In addition, he makes $3,677,280 as President, Chief Executive Officer, and Director at NeuBase Therapeutics.
Dietrich has made over 3 trades of the NeuBase Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 1,275 units of NBSE stock worth $9,856 on 9 June 2020.
The largest trade he's ever made was buying 10,000 units of NeuBase Therapeutics stock on 30 April 2020 worth over $60,000. On average, Dietrich trades about 4,175 units every 13 days since 2020. As of 9 June 2020 he still owns at least 12,525 units of NeuBase Therapeutics stock.
You can see the complete history of Dietrich S stock trades at the bottom of the page.
Dr. Dietrich A. Stephan Ph.D. serves as President, Chief Executive Officer, Director of the Company. He served as Chair of the Department of Human Genetics at the University of Pittsburgh from 2013 to 2018, and earlier, as the founding Director of the Neurogenomics Division at the Translational Genomics Research Institute (TGen) and Deputy Director of Discovery Research at TGen. Dr. Stephan is Chairman of Peptilogics, a privately held peptide therapeutics company; a director of Sharp Edge Labs, a privately held small-molecule genetic disease therapeutics company; a director of FarmaceuticalRx, a privately held pharmaceutical company developing cannabinoid-based therapies; a director of Epistemix, a population-based disease modeling company; and partner in Cyto Ventures, an early stage investment fund. In the last five years, Dr. Stephan has held director roles at Pendulum Therapeutics (formerly Whole Biome), a privately held company developing microbiome therapies; CereDx, a privately held home-base stroke detection diagnostics company; Elastogenesis, a privately held pharmaceutical company developing therapies for dermal extracellular matrix regeneration; Western Oncolytics, a privately held pharmaceutical company developing oncolytic viruses; iGenomX, a privately held company developing genome sequencing reagents; Ariel Precision Medicine, a privately held diagnostics company focused on pancreatic disease; and ParaBase, a privately held company focused on developing neonatal genetic diagnostic tests. Dr. Stephan received his B.S. in Biology from Carnegie Mellon University and his Ph.D. in Human Genetics from the University of Pittsburgh. He also completed a fellowship at the National Human Genome Research Institute. Stephan’s role as CEO of our Company, experience as the founder of Legacy NeuBase and in the biopharmaceutical industry qualify him to serve as a member of our board of directors.
As the President, Chief Executive Officer, and Director of NeuBase Therapeutics, the total compensation of Dietrich Stephan at NeuBase Therapeutics is $3,677,280. There are no executives at NeuBase Therapeutics getting paid more.
Dietrich Stephan is 50, he's been the President, Chief Executive Officer, and Director of NeuBase Therapeutics since 2019. There are 8 older and 2 younger executives at NeuBase Therapeutics. The oldest executive at NeuBase Therapeutics, Inc. is Franklyn Prendergast, 75, who is the Independent Director.
Over the last 5 years, insiders at NeuBase Therapeutics have traded over $713,184 worth of NeuBase Therapeutics stock and bought 177,514 units worth $548,788 . The most active insiders traders include Dov A Md Goldstein, Dietrich A Stephan, and Samuel Backenroth. On average, NeuBase Therapeutics executives and independent directors trade stock every 56 days with the average trade being worth of $37,929. The most recent stock trade was executed by Corp Symetryx on 14 September 2023, trading 282,445 units of NBSE stock currently worth $375,652.
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
NeuBase Therapeutics executives and other stock owners filed with the SEC include: